hydroxychloroquine has been researched along with Age-Related Macular Degeneration in 22 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To describe a series of patients with Stargardt disease (STGD1) exhibiting a phenotype usually associated with hydroxychloroquine (HCQ) retinopathy on spectral domain-optical coherence tomography (SD-OCT)." | 7.83 | Recessive Stargardt disease phenocopying hydroxychloroquine retinopathy. ( Allikmets, R; Greenstein, VC; Lee, W; Nõupuu, K; Tsang, S; Zernant, J, 2016) |
| "Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e." | 5.72 | Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report. ( Ameen Ismail, A; Hatata, RM; Sadek, SH, 2022) |
| "To report a rare case of cystoid macular edema (CME) as a presentation of acute hydroxychloroquine-related retinal toxicity." | 4.31 | Unusual Presentation of Acute Hydroxychloroquine Retinopathy. ( Cheng, CK; Lian, YY; Ma, YC, 2023) |
| "To describe a series of patients with Stargardt disease (STGD1) exhibiting a phenotype usually associated with hydroxychloroquine (HCQ) retinopathy on spectral domain-optical coherence tomography (SD-OCT)." | 3.83 | Recessive Stargardt disease phenocopying hydroxychloroquine retinopathy. ( Allikmets, R; Greenstein, VC; Lee, W; Nõupuu, K; Tsang, S; Zernant, J, 2016) |
| "In this retrospective study, we compared the mean thickness of the retinal outer band (consisting of the Bruch's membrane and retinal pigment epithelium layer), as measured by optical coherence tomography (OCT), of 54 eyes of 27 hydroxychloroquine-treated rheumatoid arthritis patients (study group), 40 eyes of 20 healthy similar aged individuals (control group I), and 22 eyes of 11 non-hydroxychloroquine-treated rheumatoid arthritis patients (control group II)." | 3.79 | A retrospective evaluation of the effect of hydroxyquinine on RPE thickness. ( Beiran, I; Chassid, O; Pikkel, J; Sharabi-Nov, A, 2013) |
| "C-wave and ERG records have been taken from patients with juvenile macular degeneration, cone dysfunction syndrome, non exudative macular degeneration and from patients who have taken hydroxychloroquine for more than a year." | 3.67 | [C-wave changes in macular diseases]. ( Brouza, D; Moschos, M; Panagakis, E, 1989) |
| " An intake of HCQ is safe during pregnancy and breastfeeding according to the current state of knowledge and is protective for mother and child in patients with systemic lupus erythematosus." | 2.66 | [Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search]. ( Detert, J; Fiehn, C; Hadjiski, D; Krüger, K; Ness, T; Specker, C; Weseloh, C, 2020) |
| " A higher dosage per kg body mass, long therapy duration, presence of keratopathy and renal or hepatic dysfunction are probably associated with an increased risk to develop a maculopathy/retinopathy." | 2.45 | [Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up]. ( Pluta, JP; Rüther, K, 2009) |
| "Hydroxychloroquine (HCQ) is an anti-malarial drug but also widely used to treat autoimmune diseases like arthritis and lupus." | 1.72 | Hydroxychloroquine Causes Early Inner Retinal Toxicity and Affects Autophagosome-Lysosomal Pathway and Sphingolipid Metabolism in the Retina. ( Basu, SK; Chalfant, CE; Chiu, CY; Cole, J; Khanam, S; Mandal, N; Mondal, K; Pandya, HK; Porter, H; Shah, V; Stephenson, DJ, 2022) |
| "Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e." | 1.72 | Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report. ( Ameen Ismail, A; Hatata, RM; Sadek, SH, 2022) |
| "Hydroxychloroquine (HCQ) maculopathy is irreversible; primary prevention is done by regular monitoring." | 1.62 | An objective method of diagnosing hydroxychloroquine maculopathy. ( Hasan, H; Lotery, A; Price, EJ; Smith, GT, 2021) |
| " The risk of this severe, irreversible ophthalmological complication significantly increases with duration of treatment (> 5 years) and dosage of medication (for CQ > 2." | 1.48 | [Chloroquine retinopathy]. ( Lavrijsen, APM; Nguyen, AL; Tan, AN, 2018) |
| "Hydroxychloroquine (HCQ) has a low risk of retinal toxicity which increases dramatically with a cumulative dose of >1000 g." | 1.43 | A possible early sign of hydroxychloroquine macular toxicity. ( Brandao, LM; Palmowski-Wolfe, AM, 2016) |
| "This report describes the case of an appropriately dosed patient who developed maculopathy <8 years after starting hydroxychloroquine (HCQ) therapy for systemic lupus erythematosus." | 1.31 | Early hydroxychloroquine macular toxicity. ( Warner, AE, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 8 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Bijan, S | 1 |
| Yu, SY | 1 |
| Kiri, G | 1 |
| Bhaleeya, S | 1 |
| Tzekov, R | 1 |
| Mondal, K | 1 |
| Porter, H | 1 |
| Cole, J | 1 |
| Pandya, HK | 1 |
| Basu, SK | 1 |
| Khanam, S | 1 |
| Chiu, CY | 1 |
| Shah, V | 1 |
| Stephenson, DJ | 1 |
| Chalfant, CE | 1 |
| Mandal, N | 1 |
| Bajka, A | 1 |
| Toro, M | 1 |
| Kniestedt, C | 1 |
| Zweifel, S | 1 |
| Lian, YY | 1 |
| Ma, YC | 1 |
| Cheng, CK | 1 |
| Ameen Ismail, A | 1 |
| Sadek, SH | 1 |
| Hatata, RM | 1 |
| Sharma, M | 1 |
| Kumar, M | 1 |
| Dutta, D | 1 |
| Fiehn, C | 1 |
| Ness, T | 1 |
| Weseloh, C | 1 |
| Specker, C | 1 |
| Hadjiski, D | 1 |
| Detert, J | 1 |
| Krüger, K | 1 |
| Hasan, H | 1 |
| Lotery, A | 1 |
| Price, EJ | 1 |
| Smith, GT | 1 |
| Nguyen, AL | 1 |
| Tan, AN | 1 |
| Lavrijsen, APM | 1 |
| Modi, YS | 1 |
| Singh, RP | 1 |
| Messiant, V | 1 |
| Defoort-Dhellemmes, S | 1 |
| Smirnov, V | 1 |
| Geamănu Pancă, A | 1 |
| Popa-Cherecheanu, A | 1 |
| Marinescu, B | 1 |
| Geamănu, CD | 1 |
| Voinea, LM | 1 |
| Nõupuu, K | 1 |
| Lee, W | 1 |
| Zernant, J | 1 |
| Greenstein, VC | 1 |
| Tsang, S | 1 |
| Allikmets, R | 1 |
| Brandao, LM | 1 |
| Palmowski-Wolfe, AM | 1 |
| Pluta, JP | 1 |
| Rüther, K | 1 |
| Gorovoy, I | 1 |
| Gorovoy, JB | 1 |
| Pikkel, J | 1 |
| Chassid, O | 1 |
| Sharabi-Nov, A | 1 |
| Beiran, I | 1 |
| Gaynes, BI | 1 |
| Vanheesbeke, A | 1 |
| Paulus, HE | 1 |
| Warner, AE | 1 |
| Moschos, M | 1 |
| Brouza, D | 1 |
| Panagakis, E | 1 |
4 reviews available for hydroxychloroquine and Age-Related Macular Degeneration
| Article | Year |
|---|---|
[Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search].
Topics: Antimalarials; Antirheumatic Agents; Child; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2020 |
Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review.
Topics: Autoimmune Diseases; Humans; Hydroxychloroquine; Incidence; Macular Degeneration; Risk Factors | 2014 |
[Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up].
Topics: Antimalarials; Chloroquine; Diagnostic Techniques, Ophthalmological; Dose-Response Relationship, Dru | 2009 |
[Retinal pigment epithelium--the point about safety of antimalarial agents].
Topics: Aged; Animals; Antimalarials; Chloroquine; Cisplatin; Humans; Hydroxychloroquine; Macular Degenerati | 2007 |
18 other studies available for hydroxychloroquine and Age-Related Macular Degeneration
| Article | Year |
|---|---|
Effect of spatial averaging on the amplitude ring ratio in multifocal electroretinography.
Topics: Electroretinography; Female; Humans; Hydroxychloroquine; Macular Degeneration; Male; Retina; Retinal | 2022 |
Hydroxychloroquine Causes Early Inner Retinal Toxicity and Affects Autophagosome-Lysosomal Pathway and Sphingolipid Metabolism in the Retina.
Topics: Animals; Antirheumatic Agents; Autophagosomes; Hydroxychloroquine; Lysosomes; Macular Degeneration; | 2022 |
Decrease in Visual Acuity in a 77-Year-old Woman with Age-Related Macular Degeneration after a SARS-CoV-2 Infection Treated with Hydroxychloroquine.
Topics: Aged; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Macular Degeneration; S | 2022 |
Unusual Presentation of Acute Hydroxychloroquine Retinopathy.
Topics: Adult; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Fluorescein An | 2023 |
Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report.
Topics: Adult; Antirheumatic Agents; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2022 |
Hydroxychloroquine in diabetes and dyslipidaemia: primum non nocere.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Enzyme Inhibitors; Human | 2020 |
An objective method of diagnosing hydroxychloroquine maculopathy.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Macular Degeneration; Male; Middle Aged; R | 2021 |
[Chloroquine retinopathy].
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; | 2018 |
Bull's-Eye Maculopathy Associated with Hydroxychloroquine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Macular Degeneratio | 2019 |
[Atypical hydroxychloroquine maculopathy in an Asian woman with lupus].
Topics: Adult; Asian People; Female; Genetic Predisposition to Disease; Humans; Hydroxychloroquine; Laos; Lu | 2019 |
Recessive Stargardt disease phenocopying hydroxychloroquine retinopathy.
Topics: Adult; Antimalarials; ATP-Binding Cassette Transporters; Child; Electroretinography; Female; Genes, | 2016 |
A possible early sign of hydroxychloroquine macular toxicity.
Topics: Adolescent; Antirheumatic Agents; Dermatomyositis; Electroretinography; Female; Humans; Hydroxychlor | 2016 |
Advances in ophthalmic monitoring for hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Dose-Response Relationship, Drug; Dru | 2013 |
A retrospective evaluation of the effect of hydroxyquinine on RPE thickness.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Bruch Membrane; Female; | 2013 |
Sparing of age-related macular degeneration in rheumatoid arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, R | 2006 |
An overview of benefit/risk of disease modifying treatment of rheumatoid arthritis as of today.
Topics: Arthritis, Rheumatoid; Azathioprine; Chloroquine; Cyclophosphamide; Female; Gold; Humans; Hydroxychl | 1982 |
Early hydroxychloroquine macular toxicity.
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Macular Degeneration | 2001 |
[C-wave changes in macular diseases].
Topics: Adolescent; Adult; Aged; Aging; Child; Electroretinography; Humans; Hydroxychloroquine; Macula Lutea | 1989 |